Brought to you by 
Bayer enters major alliance with CuraGen
26 Apr 2002
Executive Summary
Bayer and functional genomics company CuraGen have entered into two agreements. In the first, a 15-year deal, they will discover, develop, and market small-molecule drugs to treat obesity and adult onset diabetes. In the second, Bayer will utilize CuraGen's genomic technologies to evaluate its pharmaceutical compounds in all disease areas.
Deal Industry
- Pharmaceuticals
-
Biotechnology
- Pharmacogenetics-Pharmacogenomics
-
Drug Discovery Tools
- Bioinformatics
- Genomics-Proteomics
Deal Status
- Final
Deal Type
-
Alliance
- Co-Promotion
- Includes Contract
- Includes Equity
- Includes Royalty or Profit Split Information
- R&D and Marketing (Licensing)
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Bayer enters major alliance with CuraGen
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice